Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”) (Paris:GV),a Euronext-listed biotechnology company developing tools and services for the highly accurate characterization of DNA sequences, is pleased to announce the selection of Cambridge Consutants, a world-leading product development and technology consultancy, part of Capgemini Invent1, to jointly develop the next generation of a technology platform for the analysis of structural and functional genome modifications.
The DNA combing technology, pioneered by Genomic Vision, will help achieve significantly higher throughput, reduced hands-on time and improved user experience through the collaboration. A fully integrated system, starting from DNA sample preparation to image analysis driven by Artificial Intelligence, will be developed to offer an automated workflow and excellent user experience.
Genomic Vision’s DNA combing technology enables the detection of single DNA molecules and chromosomal rearrangements, identifying features of the genome that other methods cannot assess. The current technology was most suitable for research purposes. The future platform will improve performance by reaching a higher throughput compatible with pharmaceutical requirements.
“This collaboration is truly about combining the strengths of our two companies to develop a disruptive technological platform to achieve our ambitious strategic objectives,” said Andrii Kulakovskyi, Ph.D., Technical Director of Genomic Vision. “This novel platform will be a game-changer in Genomic Vision strategic plans.”
Eric Wilkinson, CEO Cambridge Consultants commented: “Genomic Vision’s technology and applications are very impressive. Together, we have all the expertise, skills and tools to significantly drive innovation in this technology to unveil genome modifications.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
